Lenvatinib is a multi-target tyrosine kinase inhibitor mainly used to treat malignant tumors such as thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma, exerting anti-tumor effects by inhibiting angiogenesis and tumor growth.

1. Main indications

(1) Differentiated thyroid cancer: used for locally recurrent or metastatic cases that are difficult to treat with radioactive iodine.

(2) Hepatocellular carcinoma: first-line treatment for unresectable advanced liver cancer patients.

(3) Renal cell carcinoma: Combination therapy with everolimus for advanced cases that have previously received anti angiogenic therapy.

2. Mechanism of action

(1) Target inhibition: Selective inhibition of receptors such as VEGFR1-3, FGFR1-4, PDGFR α, RET, and KIT.

(2) Anti angiogenesis: Blocking the VEGF signaling pathway and reducing tumor angiogenesis.

(3) Direct anti-tumor effect: By inhibiting pathways such as FGFR, it hinders tumor cell proliferation and metastasis.

3 Clinical Advantages

(1) Liver cancer efficacy: In REFELECT studies, it showed an objective response rate superior to sorafenib.

(2) Combination therapy: Combined with PD-1 inhibitors can enhance the efficacy of immunotherapy.

(3) Convenient administration: once daily oral administration, high patient compliance.